氯吡格雷片联合阿托伐他汀片用于冠心病经皮冠状动脉介入术术后患者的临床研究  

Clinical trial of clopidogrel tablets combined with atorvastatin tablets in the treatment of patients with coronary heart disease after percutaneous coronary intervention

作　　者：朱静燕 杨渊 侯雪 张茜[1] 徐桂冬[2] 闫欣欣[1] ZHU Jing-yan;YANG Yuan;HOU Xue;ZHANG QIAN;XU Gui-dong;YAN Xin-xin(Department of Pharmacy,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Suzhou 215008,Jiangsu Province,China;Department of Cardiology,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Suzhou 215008,Jiangsu Province,China)

机构地区：[1]南京医科大学附属苏州医院苏州市立医院药剂科,江苏苏州215008 [2]南京医科大学附属苏州医院苏州市立医院心内科,江苏苏州215008

出　　处：《中国临床药理学杂志》2022年第11期1166-1169,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金青年基金资助项目(82000379);江苏省自然科学基金青年基金资助项目(BK20190189);苏州市民生科技计划项目-医疗卫生应用基础研究基金资助项目(sys2018090,sysd2020192)。

摘　　要：目的观察氯吡格雷片联合阿托伐他汀片用于冠心病(CHD)经皮冠状动脉介入术(PCI)术后患者的临床疗效及安全性。方法将60例患者按治疗方法分为对照组30例和试验组30例。PCI术后,对照组给予阿托伐他汀片每次20 mg,每晚1次,口服;试验组在对照组治疗的基础上,给予氯吡格雷片每次75 mg,qd,口服。2组患者均持续治疗24周以上。比较2组患者的临床疗效、超敏C反应蛋白(hs-CRP)和血脂,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为96.67%(29例/30例)和76.67%(23例/30例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的hs-CRP分别为(1.01±0.52)和(1.51±0.87)mg·L^(-1),三酰甘油分别为(1.08±0.39)和(1.44±0.46)mmol·L^(-1),总胆固醇分别为(3.24±0.42)和(3.63±0.85)mmol·L^(-1),高密度脂蛋白胆固醇分别为(1.21±0.30)和(1.05±0.19)mmol·L^(-1),低密度脂蛋白胆固醇分别为(1.80±0.39)和(2.13±0.51)mmol·L^(-1),差异均有统计学意义(均P<0.05)。2组患者治疗期间均未发生药物不良反应。结论氯吡格雷片联合阿托伐他汀片用于CHD PCI术的临床疗效确切,其能有效地改善血脂水平,且安全性较好。Objective To observe the clinical efficacy and safety of clopidogrel tablets combined with atorvastatin tablets in the treatment of patients with coronary heart disease(CHD)after percutaneous coronary intervention(PCI).Methods According to different treatment methods,60 patients with coronary heart disease after PCI were divided into control group(n=30 cases)and treatment group(n=30 cases).Control group was given atorvastatin tablets 20 mg per time,every night,orally.Treatment group received clopidogrel 75 mg per time,once a day,orally,on the basis of control group.Two groups were treated for more than 24 weeks.The clinical efficacy,high sensitivity C-reactive protein(hs-CRP)and blood lipid levels,and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 96.67%(29 cases/30 cases)and 76.67%(23 cases/30 cases)with significant difference(P<0.05).After treatment,hs-CRP of treatment and control groups were(1.01±0.52)and(1.51±0.87)mg·L^(-1),triglyceride were(1.08±0.39)and(1.44±0.46)mmol·L^(-1),total cholesterol were(3.24±0.42)and(3.63±0.85)mmol·L^(-1),high density lipoprotein cholesterol were(1.21±0.30)and(1.05±0.19)mmol·L^(-1),low density lipoprotein cholesterol were(1.80±0.39)and(2.13±0.51)mmol·L^(-1),and the differences were statistically significant(all P<0.05).No adverse drug reactions occurred in 2 groups during treatment.Conclusion Clopidogrel tablets combined with atorvastatin tablets have a definitive clinical efficacy and safety in the treatment of patients with CHD after PCI,which can effectively improve the level of blood lipid and has good safety.

关 键 词：氯吡格雷片 阿托伐他汀片 冠心病 经皮冠状动脉介入术 安全性评价 

分 类 号：R972[医药卫生—药品]